Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel's drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.